Juvenile myelomonocytic leukaemia (JMML) is a rare, aggressive myeloproliferative neoplasm that responds poorly to conventional chemotherapy. [1] [2] [3] With the exception of rare cases of spontaneous remission seen in children with specific molecular mutations, allogeneic haematopoietic SCT (HSCT) is the only curative therapy. Myeloablative conditioning is widely considered to be essential to eradicate leukaemic clones and to faciliate engraftment. Owing to historically high rates of treatment-related mortality (TRM) in children with JMML, efforts are ongoing to develop newer approaches to HSCT therapy to reduce toxicities, including reduced-toxicity myeloablative conditioning regimens. We present pilot data on three children who underwent HSCT with such an approach.
A search of our institutional database was performed, and three patients were identified with a diagnosis of JMML who received a reduced-toxicity regimen. A retrospective chart review of the clinical records of the three cases was subsequently conducted to gather data. The database and clinical records were housed at Alberta Children's Hospital in Calgary, Alberta, Canada. This retrospective study was approved by the University of Calgary Conjoint Health Research Ethics Board.
All patients received the same regimen consisting of i.v. BU (4 mg/kg/day once daily, days − 5 to − 2), i.v. fludarabine (50 mg/ m 2 /day, days − 6 to − 2), i.v. rabbit ATG (0.5 mg/kg on day − 3 and 2.5 mg/kg/day on days − 2 and − 1) and 400 cGy of TBI on day − 1. BU pharmacokinetics were calculated based on an institutional practise of test dosing before the administration of full dosing, usually day − 7. The target area under the curve (AUC) was 3800 μM Á min. GVHD prophylaxis consisted of CYA in combination with MTX for live donor stem cell products or methylprednisolone for umbilical cord blood (UCB) infusions. Filgrastim was given post HSCT with UCB products. Institutional antimicrobial prophylaxis included acyclovir, fluconazole and metronidazole. Seizure prophylaxis with lorazepam was given one day before BU exposure and continued until 1 day after completion.
All three cases met modified JMML diagnostic criteria. 1, 3 Table 2 details the post-HSCT outcomes for all three cases. Two of the children are cured of their disease and one died of perioperative complications in the setting of relapse and second malignancy.
JMML is characterised by excessive production of myeloid cells with associated tissue infiltration. 1, 2 In over 90% of cases, a molecular mutation resulting in myeloid proliferation is identified. 3 Generally diagnosed before 2 years of age, JMML is almost uniformly fatal if left untreated. 1, 3 Classic presentations include fever, hepatosplenomegaly, rash, leucocytosis with left shift, anaemia and thrombocytopaenia. Excessive inflammatory signalling and tissue infiltration can result in life-threatening cardio-respiratory instability, particularly with lung infiltration. While cases of spontaneous remission have been reported they are rare; chemotherapy can reduce symptoms and signs of tissue infiltration and achieve some stability in children who are unwell as a result; however, the only curative therapy is HSCT. [1] [2] [3] Although allogeneic HSCT is the only curative option, relapse rates remain high (35%) and TRM is also unacceptably high (15%) with myeloablative conditioning. 4 Given that the highest rates of EFS in most series are around 50%, newer approaches are needed to lower rates of relapse and TRM. Eradication of malignant clones at the stem cell level is believed to be necessary to cure JMML and HSCT conditioning approaches have historically maximised alkylating agent exposure with this goal in mind. Such an approach carries the aforementioned risks of morbidity and mortality, in a host who may have poor performance status with organ dysfunction at the time of HSCT.
Newer approaches to myeloablative conditioning such as 'reduced toxicity' regimens are gaining popularity. 1, [5] [6] [7] For diseases such as JMML with already high rates of TRM related to organ dysfunction and, at times, poor performance status at the time of HSCT, reduced toxicity of therapy is of great interest. 3, 8 Such regimens retain myeloablation with drugs such as BU (generally considered myeloablative at total dosing ⩾ 10 mg/kg) while substituting other alkylating agents for less toxic chemotherapeutic agents that are immunosuppressive, but have been associated with lower rates of TRM and complications, such as sinusoidal obstructive syndrome (SOS). [7] [8] [9] Fludarabine has been commonly used as an immune suppressing substitute for CY with this goal in mind. 3 However, it has been suggested that reducedtoxicity regimens may not be sufficiently myeloablative to eradicate JMML clones and allow for engraftment, although some experts believe the GVL effect to be of greater importance. Debate regarding the intensity of conditioning required for curative HSCT in JMML is ongoing; during the development of the Children's Oncology Group JMML protocol ASCT1221, a myeloablative conditioning regimen was considered essential to maximise the potential for engraftment. 3 This study will compare the regimen with the best published results reported by the EWOG-MDS/EBMT consisting of BU, CY and melphalan conditioning to a BU/fludarabine approach. 4 The European group described an EFS and TRM of 52% and 13%, respectively, with the use of maximal dosing of alkylating agents. Despite often being referenced as the 'standard-of-care,' this intensive conditioning approach has not been universally accepted owing to the high rates of toxicity. Given that the Japanese Childhood MDS Study Group has safely piloted the substitution of fludarabine for CY in 10 children with JMML and excellent published outcomes using BU and fludarabine in adults with AML (often with comorbidities), the use of fludarabine to maintain efficacy but reduce toxicity is of increasing interest to cooperative groups internationally when studying the treatment of children with myeloid malignancies. 3, 5, 10, 11 Some data on adults with AML have suggested not only lower TRM, but lower rates of relapse as well. 6, 7 It should be emphasised that even in our small series we observed numerous important toxicities, including a rare form of post-transplant T-cell lymphoma. An important distinction between our protocol and those adopted by many cooperative groups is the use of 400 cGy low-dose TBI owing to local adult data showing improved efficacy in myeloid malignancies. 11 Many JMML protocols have omitted TBI in these typically young children, although it should be noted that these TBI-containing regimens have been primarily TBI-based (that is, ⩾ 900 cGy). 9 We recognise that the use of TBI in our approach can be challenged and that some of the toxicities observed may be attributed to the addition of this low-dose irradiation to the conditioning regimen, although doses of 1200 cGy for infants with ALL have been shown to be tolerable, albeit in a recipient with likely different comorbidities. 12 In summary, these data suggest that our conditioning regimen is feasible in the treatment of JMML. Such conditioning, although potentially curative, still carries notable risks for children with this disease. We propose that these pilot data justify the further study of this regimen in children with JMML, with further data regarding efficacy and toxicity for this high-risk population forthcoming from the international trial ASCT1221 led by the Children's Oncology Group. Cooperative studies are essential to increase rates of cure and lower rates of morbidity and mortality for this rare disease. Abbreviations: aGVHD = acute GVHD; HSCT = haematopoietic SCT; RSV = respiratory syncytial virus; cGVHD = chronic GVHD; JMML = juvenile myelomonocytic leukaemia.
